Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

By Andrew C. Li, K. Brown, M. Silvestre, T. Willson, W. Palinski, Christopher K. Glass. 2000

807 citations recorded by the source corpus.

Subfields: Epidemiology, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/38e887359d51021907f4c0110679c91c240a7ba7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Molecular Biology

In Physiology

Citations in the corpus

Liver X receptor signaling pathways in cardiovascular disease. (2003, background): “Treatment of atherogenic mouse models with RXR or PPAR agonists results in significant decreases in lesion development (65, 70).”
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. (2007, background): “…and other cell types (Delerive et al., 1999; Glass and Ogawa, 2006; Jiang et al., 1998; Ricote et al., 1998), and this activity has been correlated with insulin-sensitizing and antiatherogenic activities of synthetic PPARg agonists (Haffner et al., 2002; Li et al., 2000; Staels and Fruchart, 2005).”
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors (2006, background): “PPAR (cid:4) agonists have also been shown to have potent antiatherogenic effects in animal models (Li et al., 2000; Chen et al., 2001; Collins et al., 2001), and emerging data suggest protective effects in humans (Pfutzner et al., 2005).”
Androgens and cardiovascular disease. (2003, neutral): “128) and low-density lipoprotein (LDL) receptor (129) deficiency as well as in the modulating influences on these models of hypertension (130), P-selectin deficiency (131), and peroxisome proliferator activator receptor agonist (132).”
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. (2006, background): “Finally, it also remains possible that thiazolidinediones can have a directly beneficial effect on the vessel wall.(16,17) Our study has several limitations.”
Stabilization of atherosclerotic plaques: New mechanisms and clinical targets (2002, background): “Indeed, administration of PPAR-γ agonist to atherosclerosis-prone mice can not only reduce lesion size but also limit MMP expression, an action related to lesion stabilizatio”
NF-κB: pivotal mediator or innocent bystander in atherogenesis? (2001, background): “Finally, PPARγ-specific agonists inhibit the development of atherosclerosis in LDL receptor–deficient male mice (16).”